Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
76 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Pipeline Review, H2 2016', provides in depth analysis on Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted pipeline therapeutics. The report provides comprehensive information on the Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - The report reviews Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects - The report assesses Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) Overview 9 Therapeutics Development 10 Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Products under Development by Stage of Development 10 Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Products under Development by Therapy Area 11 Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Products under Development by Indication 12 Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Pipeline Products Glance 14 Late Stage Products 14 Early Stage Products 15 Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Products under Development by Companies 16 Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Products under Development by Universities/Institutes 18 Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Therapeutics Assessment 20 Assessment by Monotherapy/Combination Products 20 Assessment by Mechanism of Action 21 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Companies Involved in Therapeutics Development 26 Array BioPharma Inc. 26 Astellas Pharma Inc. 27 AstraZeneca Plc 28 Chiesi Farmaceutici SpA 29 Chroma Therapeutics Limited 30 Eli Lilly and Company 31 GlaxoSmithKline Plc 32 Synovo GmbH 33 Toray Industries, Inc. 34 Zocere, Inc. 35 Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Drug Profiles 36 ARRY-797 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 AS-1940477 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 CHF-6297 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 CHR-5623 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 losmapimod - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Peptides to Inhibit MAPK14 and MAPK11 for Rheumatoid Arthritis, Multiple Sclerosis and Pancreatic Cancer - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 ralimetinib mesylate - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Recombinant Peptide To Inhibit MAPK14 For Ischemic Stroke - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Small Molecule to Inhibit Mitogen Activated Protein Kinase 14 for Alzheimer's Disease - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Small Molecule to Inhibit p38 MAP Kinase for Undisclosed Indication - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Small Molecules to Inhibit p38alpha MAP Kinase for Inflammatory Diseases - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 SYD-003 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 VX-745 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Dormant Projects 55 Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Discontinued Products 61 Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Featured News & Press Releases 63 Aug 30, 2016: Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress 63 Aug 20, 2016: Array BioPharma Announces Clinical Data Presentation On ARRY-797 At The 2016 European Society Of Cardiology Congress 64 Dec 16, 2015: EIP Pharma announces scientific publication of results demonstrating pro-cognitive effects in aged rats of VX-745, a clinical stage selective p38 MAP kinase alpha Inhibitor 64 Oct 27, 2015: GSK provides update on LATITUDE-TIMI 60 (losmapimod cardiovascular study) 65 Jul 15, 2015: Zocere's Brain Saving" Drug Issued U.S. Patent 65 Jun 03, 2015: EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease 66 Jan 07, 2015: Zocere to Present Brain-Protecting Drug at Biotech Showcase 67 Oct 14, 2014: Zocere Showcases "Brain Saving" Drug at Life Sciences Summit in New York City 67 Oct 01, 2014: Zocere's Stroke Drug to Be Featured at BIO Investor Forum 68 Jun 05, 2014: GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome 68 Nov 06, 2012: Array BioPharma To Present Phase II Results Of ARRY-797 At 2012 American College Of Rheumatology Annual Meeting 69 Jul 31, 2012: Array BioPharma's Osteoarthritis Drug Meets Primary Endpoint In Phase II Trial 70 Jul 08, 2009: Array BioPharma Announces Top-Line Results In Two Phase I Clinical Trials 71 Oct 26, 2008: Array BioPharma's Oral p38 Inhibitor Demonstrates Significant Analgesic Benefit and Systemic Anti-Inflammatory Activity in a Phase II Trial 72 May 07, 2008: Array BioPharma Presents Additional Positive Phase II Results Of ARRY-797 In Inflammatory Pain Clinical Trial At The American Pain Society's Annual Scientific Meeting 73 Appendix 75 Methodology 75 Coverage 75 Secondary Research 75 Primary Research 75 Expert Panel Validation 75 Contact Us 75 Disclaimer 76
List of Tables
Number of Products under Development for, H2 2016 10 Number of Products under Development by Therapy Area, H2 2016 11 Number of Products under Development by Indication, H2 2016 13 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Early Stage Products, H2 2016 15 Number of Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 17 Number of Products under Investigation by Universities/Institutes, H2 2016 18 Products under Investigation by Universities/Institutes, H2 2016 19 Assessment by Monotherapy/Combination Products, H2 2016 20 Number of Products by Stage and Mechanism of Action, H2 2016 21 Number of Products by Stage and Route of Administration, H2 2016 23 Number of Products by Stage and Molecule Type, H2 2016 25 Pipeline by Array BioPharma Inc., H2 2016 26 Pipeline by Astellas Pharma Inc., H2 2016 27 Pipeline by AstraZeneca Plc, H2 2016 28 Pipeline by Chiesi Farmaceutici SpA, H2 2016 29 Pipeline by Chroma Therapeutics Limited, H2 2016 30 Pipeline by Eli Lilly and Company, H2 2016 31 Pipeline by GlaxoSmithKline Plc, H2 2016 32 Pipeline by Synovo GmbH, H2 2016 33 Pipeline by Toray Industries, Inc., H2 2016 34 Pipeline by Zocere, Inc., H2 2016 35 Dormant Projects, H2 2016 55 Dormant Projects (Contd..1), H2 2016 56 Dormant Projects (Contd..2), H2 2016 57 Dormant Projects (Contd..3), H2 2016 58 Dormant Projects (Contd..4), H2 2016 59 Dormant Projects (Contd..5), H2 2016 60 Discontinued Products, H2 2016 61 Discontinued Products (Contd..1), H2 2016 62
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
